FFA
CVKD icon

Frazier Financial Advisors’s Cadrenal Therapeutics CVKD Stock Holding History

Frazier Financial Advisors’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10
Closed -$177 – 628
2025
Q1 		$177 Buy
+10
New +$184 ﹤0.01% 563

Other funds holding CVKD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Frazier Financial Advisors's CVKD Position: Q2 2025 in Review

Frazier Financial Advisors sold out of Cadrenal Therapeutics (CVKD) in Q2 2025, closing a stake of 10 shares — an estimated $177 sold.

Frazier Financial Advisors first reported a position in CVKD in Q1 2025 and held it in 1 quarter. The position peaked at $177 in Q1 2025. 17 funds tracked by Wall St. Rank hold CVKD as of Q2 2025.

  • Frazier Financial Advisors reported no remaining Cadrenal Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Frazier Financial Advisors sold 10 Cadrenal Therapeutics shares in Q2 2025, an estimated $177.
  • Frazier Financial Advisors first reported a position in Cadrenal Therapeutics in Q1 2025 and held it in 1 quarter.
  • Frazier Financial Advisors's Cadrenal Therapeutics position peaked at $177 in Q1 2025.
  • 17 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q2 2025.

Based on Frazier Financial Advisors's 13F filing for Q2 2025, filed 28 Jul 2025.